Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,884 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.
Donia M, Harbst K, van Buuren M, Kvistborg P, Lindberg MF, Andersen R, Idorn M, Munir Ahmad S, Ellebæk E, Mueller A, Fagone P, Nicoletti F, Libra M, Lauss M, Hadrup SR, Schmidt H, Andersen MH, Thor Straten P, Nilsson JA, Schumacher TN, Seliger B, Jönsson G, Svane IM. Donia M, et al. Among authors: mueller a. Cancer Res. 2017 Sep 1;77(17):4562-4566. doi: 10.1158/0008-5472.CAN-16-3172. Epub 2017 Jun 27. Cancer Res. 2017. PMID: 28655789
Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy.
Friedrich M, Jasinski-Bergner S, Lazaridou MF, Subbarayan K, Massa C, Tretbar S, Mueller A, Handke D, Biehl K, Bukur J, Donia M, Mandelboim O, Seliger B. Friedrich M, et al. Among authors: mueller a. Cancer Immunol Immunother. 2019 Oct;68(10):1689-1700. doi: 10.1007/s00262-019-02373-1. Epub 2019 Aug 3. Cancer Immunol Immunother. 2019. PMID: 31375885 Free PMC article. Review.
Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display.
Wickström SL, Lövgren T, Volkmar M, Reinhold B, Duke-Cohan JS, Hartmann L, Rebmann J, Mueller A, Melief J, Maas R, Ligtenberg M, Hansson J, Offringa R, Seliger B, Poschke I, Reinherz EL, Kiessling R. Wickström SL, et al. Among authors: mueller a. Front Immunol. 2019 Dec 11;10:2766. doi: 10.3389/fimmu.2019.02766. eCollection 2019. Front Immunol. 2019. PMID: 31921104 Free PMC article.
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC.
Massa C, Karn T, Denkert C, Schneeweiss A, Hanusch C, Blohmer JU, Zahm DM, Jackisch C, van Mackelenbergh M, Thomalla J, Marme F, Huober J, Müller V, Schem C, Mueller A, Stickeler E, Biehl K, Fasching PA, Untch M, Loibl S, Weber K, Seliger B. Massa C, et al. Among authors: mueller a. J Immunother Cancer. 2020 Nov;8(2):e001261. doi: 10.1136/jitc-2020-001261. J Immunother Cancer. 2020. PMID: 33199511 Free PMC article.
Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study).
Zeuschner P, Hölters S, Stöckle M, Seliger B, Mueller A, Bachmann HS, Grünwald V, Christoph DC, Stenzl A, Grimm MO, Brüning F, Goebell PJ, Augustin M, Roos F, Harde J, Benz-Rüd I, Staehler M, Junker K. Zeuschner P, et al. Among authors: mueller a. Cancers (Basel). 2021 May 25;13(11):2594. doi: 10.3390/cancers13112594. Cancers (Basel). 2021. PMID: 34070677 Free PMC article.
1,884 results